XML 74 R64.htm IDEA: XBRL DOCUMENT v3.26.1
Earnings per Share - Summary of Earnings Per Share, Basic and Diluted (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Numerator    
Consolidated net income $ 468,256 $ 434,433
Less: net income/(loss) attributable to non-controlling interests 173,566 195,084
Net income attributable to Royalty Pharma plc - basic 294,690 239,349
Net income attributable to Royalty Pharma plc - diluted $ 375,223 $ 316,107
Denominator    
Weighted average Class A ordinary shares outstanding - basic (in shares) 436,790 435,480
Unvested RSUs (in shares) 163 48
Shares contingently issuable attributable to EPA Vehicle (in shares) 358 600
Weighted average Class A ordinary shares outstanding - diluted (in shares) 556,837 578,102
Earnings per Class A ordinary share - basic (in dollars per share) $ 0.67 $ 0.55
Earnings per Class A ordinary share - diluted (in dollars per share) $ 0.67 $ 0.55
Continuing Investors Partnerships    
Numerator    
Less: net income/(loss) attributable to non-controlling interests $ 78,049 $ 76,758
Add: Reallocation of net income attributable from the assumed exchanges of Class B ordinary shares $ 78,049 $ 76,758
Denominator    
Assumed exchanges of Class B ordinary shares (in shares) 115,840 141,974
Legacy Investors Partnerships    
Numerator    
Less: net income/(loss) attributable to non-controlling interests $ 63,213 $ 76,850
Founder’s Equity    
Numerator    
Less: net income/(loss) attributable to non-controlling interests 15,894 41,476
RP Holdings Class E Interests Holders    
Numerator    
Less: net income/(loss) attributable to non-controlling interests 16,410 0
Add: Reallocation of net income attributable from the assumed exchanges of Class B ordinary shares $ 2,484 $ 0
Denominator    
Assumed exchanges of Class B ordinary shares (in shares) 3,686 0